Gastric Cancer
Conditions
Interventions
A:HIPEC + chemotherapy group (clinically treated with standard chemotherapy + HIPEC):Hyperthermic intraperitoneal chemotherapy
A::Chemotherapy (The treatment is carried out using standard chemotherapy methods):None
Sponsors
Renji Hospital ,Shanghai Jiaotong University School Of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. patients voluntarily enrolled in this study by signing an informed consent form; 2. >=18 years old, both sexes; 3. presence of histologically confirmed, untreated gastric or gastroesophageal junction (GEJ) cancer with histologically confirmed predominantly adenocarcinoma cT4NxM0/cT1-3N+M0 gastric cancer; 4. ECOG score: 0 to 1; 5. no preoperative antitumor therapy against gastric cancer, including chemotherapy, radiotherapy, targeted and immunotherapy; 6. surgical specimens or tumor-containing tissue specimens by puncture can be obtained; 7. sufficient peripheral blood is available; 8. have access to at least 2 years of follow-up information.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women; 2. diagnosis of distant metastases by CT /MR/ EUS; 3. has received prior antitumor therapy, including chemotherapy, radiotherapy, or immunotherapy; 4. other malignant tumor within the last 5 years; 5. uncontrolled pleural effusion; 5. uncontrolled pleural effusion, pericardial effusion, or ascites; 6. does not have adequate organ function, such as severe abnormalities in blood, heart, lung, liver, or kidney function; 7. inability to obtain surgical tissue specimens; 8. those with extensive abdominal adhesions, high risk of fistula from gastrointestinal anastomosis, complete intestinal obstruction as well as bone marrow suppression, and severe abdominal infection; 9. other factors that, in the judgment of the investigator, may affect subject safety or compliance with the trial. For example, serious medical conditions (including psychiatric disorders) requiring comorbid treatment, serious laboratory test abnormalities, or other family or social factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor cells;Circulating tumor DNA; | — |
Countries
China
Contacts
Public ContactZizhen Zhang
Renji Hospital , Shanghai Jiao Tong University School of Medicine
Outcome results
None listed